anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
The invention relates to breast enhancing and body beautifying tablets for female. The tablets are current novel products. The tablets are prepared from 7 Chinese herbal medicines such as ligusticum and common yam rhizome. The tablets have functions of qi invigorating and blood circulation activating. With the tablets, within 3 treatment courses, females can be provided with enhanced breasts, attractive postures, healthy and beautiful body shapes, well-developed hips, curvy bodies, and sexy temperaments. With the tablets, women&#39;s self-esteem and self-confidence can be enhanced.
Use is claimed of ester polyol compounds as solvents, solvent aids or dispersion aids for organic compounds or pharmaceuticals, cosmetics, detergents, food or agrochemical agents which are poorly soluble or insoluble in lipophilic and hydrophilic media and as dispersants or continuous phases for pigment and micropigment dispersions. Use is claimed of ester polyol compounds as solvents, solvent aids or dispersion aids for organic compounds or pharmaceuticals, cosmetics, detergents, food or agrochemical agents which are poorly soluble or insoluble in lipophilic and hydrophilic media and as dispersants or continuous phases for pigment and micropigment dispersions. The ester polyol compounds are optionally in admixture with amino-functional polyol compounds of melting point below 100[deg]C or ester polyol compounds of formula R 1&gt;-O-[EO] n[PO-] mR 2&gt;(I) and are derived from: (a) polyol components comprising glycerol, 2-20C alkylene glycols, poly(2-20C alkylene)glycols (e.g. ethylene glycol or polyethylene glycols in which upto 30% of the ethylene oxide units are replaced by propylene oxide units), polyglycerols, sorbitol or pentaerythritol, and (b) acid components comprising aliphatic 3-6C carboxylic acids containing, in addition to carboxylic acid groups, hydroxy or carboxy groups. R 1&gt;1-4C alkyl; R 2&gt;H or 1-4C alkyl; n : 1-100; m : 0-n/2; EO : ethylene oxide, and PO : propylene oxide. Independent claims are also included for: (1) solutions of the organic compounds in the lipophilic and hydrophilic media; (2) dispersions of pigments and micropigments or the organic compounds in the ester polyol compounds, and (3) ester polyol/polyol-in-oil emulsions or dispersions with an oil-immiscible ester polyol/polyol phase, an oil phase and an emulsifier.
PURPOSE:To obtain an agent for suppressing the proliferation of AIDS virus, having low toxicity to living body and free from side effect by using a fluoroalkyl-containing (meth)acrylic acid copolymer, etc., having a specific molecular weight as an active component. CONSTITUTION:The objective suppressing agent contains a copolymer expressed by formula I [RF is group of formula II (X is F, Cl or H; (n1) is 1-10) or formula III ((n2) is 0-8); R1 is H or methyl; A is H, halogen or 1-5C alkyl; B is H, halogen, cyano, etc.; (p) and (q) are 1-500] and having a molecular weight of 500-500,000 or its pharmaceutically permissible alkali addition salt as an active component. The daily dose of the active component for adult is preferably 50-2,000mg for oral administration and &gt;=10mg for parenteral administration. The copolymer of formula I can be produced e.g. by reacting a compound of formula IV with a monomer of the formula CH2=CAB and methacrylic acid preferably at 0-100 deg.C for 30min to 20hr under normal pressure. The copolymer is e.g. the compound of formula V ((p) and (q) are 1-500) having a molecular weight of preferably 500-50,000.
Diethylaminopropyl 2-ethoxy -4- benzamidobenzoate is prepared by treating diethylaminopropyl 2-ethoxy -4- aminobenzoate with benzoyl chloride. Treatment with acetyl chloride similarly gives diethylaminopropyl 2-ethoxy -4- acetamidobenzoate. Acid addition salts of the products are referred to.ALSO:Anticoccidial compositions comprise a carrier and a compound (or an acid addition salt thereof) of the general formula &lt;FORM:0977093/A5-A6/1&gt; wherein A is a C2-5 alkylene radical having its two free valency bonds in different carbon atoms, R is a C1-5 alkyl or alkenyl group, - NR1R2 is a dialkylamine group (the alkyl radicals having 1-5 carbon atoms) or 1-piperidyl, 4-morpholinyl or 1-pyrrolidyl and R3 and R4 are each a hydrogen atom, a C1-5 alkyl, C1-6 alkanyl or aroyl radical (including p-halobenzoyl).  The carrier may be a poultry feedstuff or conventional materials suitable for the formulation of feed supplements for addition to the feedstuff and concentrates suitable for addition to drinking water.  The compositions may also comprise other known coccidiostats e.g. amprolium, nicarbazin, glycarbylamide, 3,5 - dinitrobenzamide and 2-methyl-3,5-dinitrobenzamide.
These infracellular vesicular vectors which contain metabolic ligands capable of being expressed inside and outside their structure have a specific affinity for the fibroblast whose membrane composition, which is modified by the introduction of metabolic ligands, results in a modulation of the synthetic activity of the target cell. They are chosen from among the artificial vesicles, capsules or spheres with a diameter which may range from 30 to 1000 nanometers used to incorporate an active substance either into an aqueous medium which fills the internal volume of the vector or into the wall itself of the said vector and then to transport this active substance to a site where it will be liberated and used for various purposes. The active ingredients are encapsulated at concentrations ranging from 0.01% to 2% (10&lt;-5&gt; - 10&lt;-2&gt;) relative to the total lipid phase.   The metabolic ligands are chosen from the initiators (fatty esters of ascorbic acid) and the modulators of cellular synthesis (collagen hydrolysate palmitate or fatty esters of hydroxyproline) which are provided with a lipophilic functional group or radical by acylation. They find applications in cosmetic compositions designed for toning up the skin tissue, for treating small indurated scars and small wrinkles, and for strengthening the epithelial layer, as well as in medicinal compositions designed to increase the synthesis of collagenases so as to resorb dense fibrous tissues into collagen I or to resorb cheloids, as well as to orient the synthesis of collagen towards a specific structure such as collagens I and III. Finally, they are applicable to the preparation of culture media for the production of peptides of the extracellular matrix and for the production of enzymatically active peptides.
Aspects of the invention described herein, concern approaches to make genetically modified T-cells comprising a chimeric antigen receptor for human therapy. In some alternatives, the methods utilize a selection and/or isolation of CD4+ and/or CD8+ T-cells from a mixed T-cell population, such as, peripheral blood or apheresis derived mononuclear cells. Once selected/isolated, the CD4+ and/or CD8+ T-cells are then activated, genetically modified, and propagated, preferably, in separate or isolated cultures in the presence of one or more cytokines, which support survival, engraftment and/or proliferation of the cells, as well as, preferably promoting or inducing the retention of cell surface receptors, such as CD62L, CD28, and/or CD27. Included herein are also methods of treatment, inhibition, amelioration, or elimination of a cancer by administering to a subject in need thereof, one or more types of the genetically engineered T-cells or compositions that comprise the genetically engineered T-cell prepared as described herein. (FIG. 11A &amp; FIG. 11B)
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a new pharmaceutical composition useful as an antibacterial agent for bacterial strains of the genus Propionibacterium.  &lt;P&gt;SOLUTION: The pharmaceutical composition comprises a new cyclic compound isolated from new Streptomyces sp. Q34752 strain and Q47152 strain as an active ingredient. The pharmaceutical composition has an excellent antibacterial activity against the bacterial strains of the genus Propionibacterium, especially Propionibacterium acnes, etc., and is useful as the antibacterial agent especially for treatment, etc., of acne vulgaris. The pharmaceutical composition has good anti-inflammatory activity and is useful for prophylaxis or therapy of various inflammatory diseases.  &lt;P&gt;COPYRIGHT: (C)2008,JPO&amp;INPIT
Devices, packaging and methodology for efficiently and repeatably creating aerosolized bursts of an insulin containing formulation are disclosed. Devices are hand-held, self-contained units which are automatically actuated at the same release point in a patient&#39;s inspiratory flow cycle. The release point is automatically determined either mechanically or, more preferably calculated by a microprocessor which receives data from a sensor making it possible to determine inspiratory flow rate and inspiratory volume. The device is loaded with a cassette comprised of an outer housing which holds a package of individual disposable collapsible containers of an insulin containing formulation for systemic delivery. Actuation of the device forces insulin formulation through a porous membrane of the container which membrane has pores having a diameter in the range of about 0.25 to 3.0 microns, preferably 0.25 to 1.5 microns. The porous membrane is positioned in alignment with a surface of a channel through which a patient inhales air. The flow profile of air moving through the channel is such that the flow at the surface of the channel is less than the flow rate at the center of the channel. The membrane is designed so that it protrudes outward at all times or made flexible so that when an insulin formulation is forced against and through the membrane the flexible membrane protrudes outward beyond the flow boundary layer of the channel into faster moving air. Because the membrane protrudes into the faster moving air of the channel the particles of aerosol formed are less likely to collide allowing for the formation of a burst of fine aerosol mist with uniform particle size.
The invention discloses a low molecular weight glycosylated chondroitin sulfate, whose weight average molecular weight is 3000-15000Da. The monosaccharide composition comprises acetyl galactosamine (D-GalNAc), glucuronic acid (D-GlcUA), fucose (L-Fuc), or its sulfuric ester (expressed in -OS03&lt;-&gt;), wherein the mole ratio of D-GalNAc to D-GlcUA to L-Fuc to -OS03&lt;-&gt; is 1: (1+/-0.3): (1+/-0.3): (3.5+/-0.5). The low molecular weight glycosylated chondroitin sulfate has a strong anti-HIV-1 virus activity, is a gp120 entry inhibitor, and can be used for preventing and/or treating AIDS. The invention also provides a method for preparing the low molecular weight glycosylated chondroitin sulfate and its composition preparation. Glycosylated chondroitin sulfate is depolymerized by the peroxide method to obtain a low molecular weight product, and then low molecular and/or high-molecular impurities of the product are removed by gel separation or ultrafiltration method. The low molecular weight glycosylated chondroitin sulfate and its medicinal composition can be prepared in the form of an injection, a lyophilized powder or a suppository.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a DNA encoding a Fas ligand mutein and chimera, and a coded protein, and also a DNA and vector for producing transformed cells for expressing the mutant or chimera Fas ligand.  &lt;P&gt;SOLUTION: The DNA and vector encoding the Fas ligand mutein and chimera, the coded protein and also the DNA for producing transformed cells for expressing the mutant or chimera Fas ligand are provided. Also, the method for treating a patient regarding autoimmune diseases or transplant rejections by administering a Fas ligand treating agent is provided. The treating agent is a polypeptide, a polynucleotide encoding the polypeptide, or a small molecule. The polypeptide includes a whole length Fas ligand polypeptide or its biologically active modified body, derivative, part, fused substance or peptide.  &lt;P&gt;COPYRIGHT: (C)2008,JPO&amp;INPIT
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a method and apparatus for extracting fucoxanthin from seaweed with a remarkably good extraction ratio and recovery ratio of fucoxanthin.  &lt;P&gt;SOLUTION: Fucoxanthin is extracted from seaweed with a high-pressure fluid. As the high-pressure fluid, a supercritical fluid, a subcritical fluid or the like is used. As a component of the fluid, for example, carbon dioxide is used. Fucoxanthin can be also extracted with the use of a mixed fluid of such a high-pressure fluid and an auxiliary solvent. Furthermore, it is also possible to carry out a pretreatment such as solar drying, freeze drying, and enzyme treatment.  &lt;P&gt;COPYRIGHT: (C)2010,JPO&amp;INPIT
FIELD: medicine, gastroenterology. SUBSTANCE: in period of supposed exacerbation one should carry out course of certain therapy for 7-10 d. Type of patient&#39;s personality should be determined to prescribe either amitryptilin or nesepam. Patients with braking type of personality - amitryptilin, with excitable type - nosepam. The suggested method enables to prevent relapses and complications. EFFECT: higher efficiency of prophylaxis. 3 cl, 2 ex
Through the hybridoma technique, we got two hybridoma cells secreting anti-CTLA-4 mAb with high affinity, which were named 22G11 and 16C11 respectively. To construct the chimeric antibody light chain and heavy chain expression vectors, the cloned anti-CTL4 antibody&#39;s light chain (VL) and heavy chain variable region cDNAs (VH) were respectively fused to the human antibody light and heavy chain constant region genes (CH). Then appropriate light and heavy chain expression vectors were co-transfected into CHO-K1 cells and the clones producing the highest amount of chimeric antibodies were selected. In the end, the purity of the two chimeric antibodies was more than ninety percent. Both of them can bind Jurkat cells specifically as did the commercial anti-CTLA-4 mAb. Western blotting analysis showed that mAbs 22G11 and 16C11 reacted with one specific band with a molecular weight of about 22 kD, further indicating that 22G11 and 16C11 specifically recognized CTLA-4 molecule. Antigen-binding activity assay demonstrated that both of the two mAbs were shown to bind well to Jurkat cells, indicating that the two chimeric antibodies were correctly constructed and produced. In the competitive binding assay, c22G11 and c16C11 could effectively compete with their respective parental mouse antibodies for binding to Jurkat cells. The avidity (mean IC50±SD) of c22G11 and c16C11 was equal to that of 22G11 and 16C11 respectively, which indicated that the chimeric antibodies possessed affinity and specificity similar to those of the original murine antibodies.
The following are claimed: (A) an attenuated Pseudomonas aeruginosa (PA) strain which has a LD50 of \-2x10&lt;-7&gt; cells in mice and which is obtd. by isolating PA in a pure state according to immunotype from patients infected with PA and subjecting the isolated strain to repeat purificn. to attenuate the strain; (B) the use of \-1 PA strain selected from (a) - (g) in the prepn. of a vaccine for immunisation against PA infection; (C) a method of immunisation against a disease caused by PA by injecting into a person a non-pathogenic antigen comprising cell wall proteins deriv. from \-1 attenuated non-pathogenic PA strain; (D) a non-pathogenic vaccine for inducing an immune response against a disease caused by PA;(E) a process for prepg. a non-pathogenic vaccine for immunisation against PA infection; (F) an incubation medium for incubating an attenuated PA strain, and (G) a therapeutic agent for treating PA infection in a patient, which comprises \-1 immunoglobulin specific against \-1 PA strain.
This invention relates to medicine and veterinary and to the method for obtaining antimicrobial complex. The purpose of invention consists in increasing antibacterial activity and extending the activity spectrum. The method consists in the fact that the lipid substrate obtained of the waste of microbiologic tuberculins&#39; production is used as the raw material. Tuberculolipids are obtained by the bacterial mass successive extraction with organic solvents. Then the lipid substrate is oxidized with hydrogen peroxide and hydrolyzed with aspartic acid at 38-40 DEGREE C during 16-30 days. The final product has increased antibacterial activity and antifungous effect.
PURPOSE: To obtain a medicine containing an inorganic phosphoric acid and adenosine and useful for increasing a total liver ATP(adenosine 5&#39;-triphosphate) pool, a total blood ATP pool and a total blood plasma ATP level by administration to a host. CONSTITUTION: This medicine contains an inorganic phosphoric acid (e.g. sodium phosphate, potassium phosphate, phosphoric acid) and adenosine. The inorganic phosphoric acid is used in the form of an aqueous solution having a pH of 6.0-7.5, preferably 6.2-7.0, usually in an inorganic phosphoric acid/adenosine equivalent ratio of 1:&gt;=1. The effective dose of the medicine is 1-1000mg/kg body/24hr on oral or topical administration, 0.01-500mg/kg body/24hr on injection, and 0.001-10mg/kg body/min on intravenous, intraabdominal or intra-arterial injection. An adenine nucleotide which is rapidly decomposed to produce the adenosine and the inorganic phosphoric acid after administration to a host may be used.
Select phytoestrogen pharmaceutical compositions and methods of use for promoting neurological health and prevention of age-related neurodegeneration, such as AD, have been developed. These select phytoestrogen formulations are composed of a number of plant-derived estrogenic molecules and/or their structural analogues and exhibit binding preference to ERβ over ERα and agonist activity in the brain. These ERβ-selective phytoestrogen formulations cross the blood-brain-barrier and promote estrogen-associated neurotrophism and neuroprotection mechanisms in the brain, without activating proliferative mechanisms in the reproductive tissues and are therefore devoid of other estrogen-associated problematic aspects. The select phytoestrogen formulations are therapeutically useful to both women and men for sustaining neurological health and preventing age-related cognitive decline and neurodegenerative disorders, such as AD. These are administered enterally, transdermally, transmucosally, intranasally or parenterally, in a dosage effective to prevent or alleviate neuronal damage, effect neuronal regeneration or sustain viability, increase expression of anti-apoptotic proteins, and/or decrease indicators of Alzheimer&#39;s Disease. The formulations preferably contain combinations of compounds, and can be formulated for daily, sustained, delayed or weekly/monthly administration. In a preferred embodiment, these are administered to women who are in menopause or post menopausal, most preferably early in menopausal.
Novel assays and reagents for determining coagulative properties of blood or plasma are disclosed, as are agents and methods for stemming bleeding. Novel ellagic acid-based activators consist essentially of aqueous solutions of ellagic acid, phenol and suitable metal ions and give defined values for a novel platelet assay also disclosed. Inventive coagulation reagents including propyl gallate or tannin are also disclosed, as are aPTT reagents having sensitivity to heparin and Factor deficiencies far superior to prior aPTT reagents. Disclosed heparin-sensitive reagents include dextran sulfate. Also disclosed is applicant&#39;s discovery that reagents including hydroxy-substituted compounds and metal ions, heretofore known to activate Hagemann Factor, also cause platelets to release Platelet Factor 3, and a series of platelet-sensitive tests found to be enabled by this discovery. These platelet-sensitive tests include assays for platelet activity, systemic lupus, platelet reserve, which can signify type II lipoprotein defects, and for Platelet Factor 4. Disclosed methods and materials for stemming bleeding center around applicant&#39;s discovery that bleeding from bleeding sites can be stopped up to six time faster by applying to the site a hemostatic agent including effective amounts of hydroxy-substituted aromatic compound and metal ion.
A composition comprising fat, fibre and, optionally, a stomach antacid is used in the treatment, prevention and/or amelioration of stereotypic behaviours such as crib-biting, stall walking, wind-sucking or wood chewing in animals such as the horse. The preferred sources of fat are highly polyunsaturated vegetable oils such as corn oil, soya oil or processed canola oil, or more saturated fats such as coconut oil, palm oil, or sunflower oil. The preferred source of fibre is any carbohydrate which is not digestible by mammalian enzymes, for example, alfalfa hay, which also contains a high protein content. At least some of the fibre should be in chopped form in the range 1-7 cm in length. Suitable stomach antacids include (a) alkaline salt compounds which can neutralise stomach acid such as aluminum phosphate and dihydro-aluminum sodium carbonate, (b) proton pump inhibitors such as the substituted benzimidazole compound, omeprazole, or (c) histamine type-2 antagonists such as ranitidine or cimetidine. Animal stereotypy may also be treated by controlling the pH of the animal&#39;s stomach using a proton pump inhibitor, such as, omeprazole, or a histamine type-2 antagonists.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a thickening agent for hair dye useful as a component of hair dyes composed mainly of an oxidizing agent, a dye and a thickening agent and provide a hair dye produced by using the thickening agent.  &lt;P&gt;SOLUTION: The thickening agent for hair dye is useful as a component of a hair dye composed mainly of an oxidizing agent, a dye and a thickening agent. The thickening agent for hair dye is composed mainly of a carboxymethylcellulose and/or its salt containing particles having particle diameter of ≥46μm and ≤177μm at a ratio of ≥50 wt.%, and having a bulk specific gravity of ≥630 g/L and ≤800 g/L and a swelling coefficient of ≤2.4. The carboxymethylcellulose and/or its salt are produced by an organic solvent process to use an organic solvent as a main solvent component in the production process. The hair dye contains 15-35 wt.% thickener for hair dye.  &lt;P&gt;COPYRIGHT: (C)2004,JPO&amp;NCIPI
The invention provides a conductive hydrogel and a preparation method and application thereof. The conductive hydrogel provided by the invention has the advantages of low modulus, high stretchability, good biocompatibility and the like. When used as a strain sensor, the sensor can be adhered to the skin surface of a human body, and cannot fall off in the movement process. The Young&#39;s modulus of the conductive hydrogel of the present invention is about 6.4kPa over a wide strain range (about 1200%). The strain sensor based on the conductive hydrogel can monitor different types of human body movements, small range such as swallowing, medium range such as finger bending, large range such as elbow bending, and the like. In addition, the movement of the human body can be monitored and distinguished by different electric signals. In addition, the conductive hydrogel can also recognize motions in different directions and output two completely opposite electric signals (positive and negative), so that the application range of the hydrogel strain sensor is greatly widened.